Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (9)	9/12/2005 7:15:05 AM
From: SnowShredder	Respond to of 251

Cytori Therapeutics Demonstrates Adipose-Derived Adult Stem and Regenerative Cells Enhance Cardiac Function in Preclinical Study fwiw... biz.yahoo.com Best of Luck, SS >>>> Cytori Therapeutics Demonstrates Adipose-Derived Adult Stem and Regenerative Cells Enhance Cardiac Function in Preclinical Study Monday September 12, 2:00 am ET Data Featured in One of Four Cytori Presentations at Annual Adipose Biology Meeting SAN DIEGO--(BUSINESS WIRE)--Sept. 12, 2005--Cytori Therapeutics, Inc. (Frankfurt:XMP - News) today announced preclinical results that support therapeutic opportunities for adult stem and regenerative cells derived from adipose, also known as fat tissue, in the treatment of cardiac injury following acute myocardial infarction (heart attack). These data, along with three other Cytori presentations, are being featured at the third annual International Fat Applied Technology Society conference September 10-13, 2005 in Charlottesville, Virginia. In a presentation entitled, "Adipose tissue-derived stem cells enhance cardiac function following surgically induced myocardial infarction," Cytori, in collaboration with researchers from the University of California, Los Angeles, illustrated that adipose derived stem and regenerative cells can improve left ventricular function after an acute myocardial infarction, or heart attack. In the study, rats were injected in the left ventricle with either adipose derived stem and regenerative cells or saline solution following heart attack. After 12 weeks, rats treated with adipose derived stem and regenerative cells demonstrated significant improvements in commonly accepted measures of heart function including contractility, ejection fraction (pumping of blood), tissue damage and other measures. "These findings, combined with our additional data presented by Cytori at the conference, confirm the broad therapeutic opportunities for adipose stem and regenerative cells in multiple disease areas, including cardiovascular injury," stated Christopher J. Calhoun, Chief Executive Officer for Cytori Therapeutics. "The ability of these stem cells to contribute to the repair of multiple tissue types is particularly important given that adipose tissue is the most abundant known source of adult stem cells." Additional presentations at the International Fat Applied Technology Society conference by Cytori and its collaborators include: "Adipose-derived stem cells express multiple genes in common with embryonic stem cells: are adult stem cells more plastic than we think?" which discusses research indicating that adult stem cells may have greater differentiation potential than previously thought "Adipose-derived stem cells in experimental animals: relevance to clinical studies," which shows that large animals such as dogs and pigs may provide a good proxy for predicting the effects of adipose stem cells in humans "Regulatory affairs and the FDA," a panel involving Cytori President Marc H. Hedrick, M.D., discussing the clinical development of adipose-derived stem cell products About Cytori Therapeutics Cytori Therapeutics (Frankfurt:XMP - News) is discovering and developing proprietary cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution(TM) system to isolate and concentrate a patient's own stem cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made. -------------------------------------------------------------------------------- Contact: Cytori Therapeutics, Inc. Tom Baker, 858-458-0900 (Media/U.S. Investors) tbaker@cytoritx.com or Stefanie Bacher, 858-458-0900 (International Investors) sbacher@cytoritx.com -------------------------------------------------------------------------------- Source: Cytori Therapeutics, Inc.